BLISSGVS

- BSE and NSE imposed a fine of ₹1,80,000 each (excluding GST) on Bliss GVS Pharma Limited for non-compliance with Regulation 17(1) of SEBI Listing Regulations regarding board composition. - The company has duly paid the imposed fines to both stock exchanges. - There is no material financial impact other than the payment of the fines.

- Bliss GVS Pharma Limited announced that its wholly-owned subsidiary, Asterisk Lifesciences Ltd, UK, has received marketing authorization from the MHRA for Mesalazine 1g Suppositories.

- Board of Directors approved the Unaudited Standalone and Consolidated Financial Results for the quarter and half year ended September 30, 2026. - Meeting held on October 29, 2026, commenced at 2:30 p.m. and concluded at 4:00 p.m. - Detailed financial result tables were not included in the filing text.

- Bliss GVS Pharma Limited granted 2,95,000 stock options under the Employee Stock Option Plan 2019 on October 29, 2026. - Each stock option is convertible into one equity share of face value Re. 1/- at an exercise price of Rs. 43/- per option. - Options vest in 4 equal annual instalments over 4 years with a minimum vesting period of 1 year.